Want to join the conversation?
$LLY said that U.S. FDA approved Portrazza, a necitumumab injection for IV use, 800 mg/50 mL in combination with gemcitabine & cisplatin, for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC). The approval was based on the results of a Phase III trial named SQUIRE.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?